Published in Clinical Trials Week, December 6th, 2004
"Aprotinin is frequently administered systemically in patients undergoing cardiopulmonary bypass to preserve platelet function and ameliorate excessive activation of fibrinolysis," scientists in Germany explained. "More recently, aprotinin topically applied in the pericardial cavity was also found to improve postoperative blood loss."
"However, platelet activation was not reduced locally during surgery," noted P.N. Khalil and colleagues at the University of Hamburg. "Hence, we investigated in the present prospective, in a randomized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.